Farmas USA

EXEL

Carga de Blackrock

https://www.sec.gov/Archives/edgar/data/939767/000021545719001653/0000215457-19-001653-index.htm

RVNC

Nota de Stifel de ayer noche:

Initiating coverage of Revance Therapeutics with a Buy Rating and $50 PT. The neurotoxin space — owned by Botox AGN — is finally evolving after years of innovation stagnation: everything from consumer marketing to value to product efficacy is getting a revamp. Unseating Botox may not be likely, but being the innovative product in a sea of “like” choices is an enviable position for RVNC, in our view. We estimate a procedure penetration of 20% share at peak, with potential for greater upside for both cosmetic and therapeutic.

TEVA

Teva Pharmaceutical Industries Limited is expected* to report earnings on 02/13/2019 before market open. 

Los MACDs diarios de IBB y XBI empezando a mostrar el color rojo … 

En el Spy estan aguantando como jabatos el 262, de perderlo no se, no se (de todos modos esperaran como siempre al cierre EU).

CNAT vamos que cerramos el gap

Pico unas cuantas a 4,1

TGTX 1h

hoy el charles schwab ha colocado HZNP SEM Y NXGN como  recomendada dentro de small cap growth